

Express Mail No. **EV 473 971 413 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Siegfried HEKIMI et al.

Confirmation No.:

9018

Serial No.:

10/800,333

Art Unit:

1633

Filed:

March 12, 2004

Examiner:

Sajjadi, Fereydoun

Ghotb

For:

Screening Assays For Targets And

Attorney Docket No:

11202-009-999

Drugs Useful In Treatment And Prevention Of Lipid Metabolism

Disorders

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

06/01/2007 TTRAN1

00000002 503013

10800333

02 FC:1806

189.09 DA

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references coming to the attention of Applicant or attorneys or agents for Applicant which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicant hereby direct the Examiner's attention to the references listed on the attached List of References Cited By Applicant, copies of which are enclosed.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Consequently, Applicant respectfully declines to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicant submits herewith a "List of References Cited by Applicant" instead of "List of Prior Art Cited."

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application.

In accordance with 37 C.F.R. § 1.97(c) and § 1.17(p), the fee required has been estimated to be \$180.00. Please charge the required fee to Jones Day Deposit Account No. 50-3010. A copy of this sheet is enclosed.

Respectfully submitted,

Date:

May 30, 2007

Laura A. Coruzzi

30,742

(Reg. No.)

By:

T. Christopher Tsang

Dec No

y:

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939





Express Mail No.: <u>EV 473 971 413 US</u> Sheet 1 of 2

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11202-009-999	10/800,333
APPLICANT	
Hekimi et al.	
FILING DATE	ART UNIT
March 12, 2004	1633

			U.S. PA	ATENT DOCUMENTS		
*Examiner Initial		Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevan Passages Or Relevant Figures Appear	
	A01	5,827,875	10/27/98	Dickson, Jr.		
	A02	6,288,234	09/11/01	Griffin		
	r	Foreign Patent Document	FOREIGN	PATENT DOCUMENTS	Pages, Columns, Lines, Where	
		Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Relevant Passages Or Relevant Figures Appear	

Examiner	1	(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item	
Initials		(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher,	т
		city and/or country where published)	1
	C01	BERRIOT-VAROQUEAUX et al., 2000, "The role of the Microsomal Triglyceride Transfer Protein in Abetalipoproteinemia." Annual Rev. of Nutri., 20:663-697 Annul Rev Inc.	
	C02	BRAECKMAN et al., 2002, "No reduction of energy metabolism in Clk mutants." Mech Aging Devel 123: 1447-1456	
	C03	BRANICKY et al., 2001, "Phenotypic and supressor analysis of defecation in clk-1 mutants reveals that reaction to changes in temperature is an active process in Caenorhabditis elegans." Genetics 159(3): 997-1006	
	C04	BULL et al., 1998, "A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis" Nature Genet 18:219-224	
	C05	BULL, 2002, "Hereditary forms of intrahepatic cholestais." Current Opin. In Genet & Dev. 12(3): 336-342	
	C06	CROWDER et al., 2001, "Enantiospecificity of cholesterol function in vivo." J. Biol. Chem. 276:44369-44372	
	C07	EWBANK et al., 1997, "Structural and functional conservation of the Caenorhabditis elegans timing gene clk-1" Science 275:980-983	
	C08	FELKAI et al., 1999, "CLK-1 controls respiration, behavior and aging in the nematode Caenorhabditis elegans." EMBO J. 18:1783-1792	
	C09	GENBANK Accession No. 045104, 1998, "Genome sequence of the nematode C. Elegans, a platform for investigating biology." C. Elegans Sequencing Consortium	
	C10	GENBANK Accession No. Q9TXV2, 2000, "Genome sequence of the the nematode C. elegans. a platform for investigating biology. The C. Elegans sequencing consortium.	
	C11	GENBANK Accession No. AU209190, 2001, "C. elegans cDNA clone: yk1011f11: 5'end"	
	C12	GENBANK Accesion No. BJ106621, 2002, "C. elegans cDNA clone yk1087b02. 5' end"	
	C13	GUO et al., 2001, "Changes in expression of antioxidant enzymes affect cell-mediated LDL oxidation and oxidized LDL-induced apoptosis in mouse aortic cells." Arterioscler Thromb Vasc Biol 21:1131-1138	
	C14	HARRIS et al., 2003, "FIC1, a P-type ATPase linked to cholestatic liver disease, has homologues (ATP8B2 and ATP8B3) expressed throughout the body." Biochemica & Biophysica Acta 1633(2):127-131	
	C15	IWASAKI et al., 1995, "Genes that control a temperature-compensated ultradian clock in Caenorhabditis elegans." Proc. Natl. Acad. Sci 92:10317-10321	
	C16	LARSEN et al., 2002, "Extension of life-span in Caenorhabditis elegans by a diet lacking coenzyme Q." Science 295(5552):120-123	

NYI-3993112v1

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail No.: <u>EV 473 971 413 US</u>

LIST OF REFERENCES	CITED BY	APPLICANT
--------------------	-----------------	------------------

(Use several sheets if necessary)

ATTY. DOCKET NO. 11202-009-999	APPLICATION NO. 10/800,333
APPLICANT Hekimi et al.	
FILING DATE March 12, 2004	ART UNIT 1633

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials				
	C17	LU et al., 2001, "Dietary cholesterol absorption; more than just bile." Trends in Endo. & Metab. 12(7): 314-320		
	C18	MANN et al., 1999, "The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins" J. Mol. Biol. 285:391-408		
	C19	MCKAY et al., 2002, "C. elegans: A model for exploring the genetics of Fat storage" Develop. Cell 4:131-142		
	C20	MIYADERA et al., 2001, "Altered quinone biosynthesis in the long-lived clk-1 mutants of Caenorhabditis elegans." J. Biol. Chem 276:7713-7716		
	C21	NAKAMUTA et al., 1996, "Mouse microsomal triglyceride transfer protein large subunit: cDNA cloning, tissue-specific expression and chromosomal localization." Genomics 33:313-316		
	C22	SASKIA et al., 2001, "FIC1 Disease: A spectrum of Intrahepatic Cholestatic Disorder." Seminars in Liver Dis. 21(4):535-544		
	C23	SHIBATA et al., 2003, "Redox regulation of germline and vulval development in Caenorhabditis elegans." Science 302(5651): 1779-1782		
	C24	STENMARK et al., 2001, "A new member of the family of di-iron carboxylate proteins. Coq7 (clk-1), a membrane-bound hydroxylase involved in ubiquinone biosynthesis." J. Biol. Chem. 276:33297-300		
	C25	WATTS et al., 2003, "Deficiencies in C20 polyunsaturated fatty acids cause behavioral and developmental defects in Caenorhabditis elegans fat-3 mutants." Genetics 163(2):581-589		
	C26	WONG, 1995, "Mutations in the CLK-1 Gene of Caenorhabditis Elegans Affect Development and Behavioral Timing." Genetics 139(3):1247-1259		

NYI-3993112v1

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.